The transcription factor forkhead box M1 (FOXM1) is a validated oncoprotein in solid cancers, but its role in malignant plasma cell tumors such as multiple myeloma (MM) is unknown. We analyzed publicly available MM data sets and found that overexpression of FOXM1 prognosticates inferior outcome in a subset (~15%) of newly diagnosed cases, particularly patients with high-risk disease based on global gene expression changes. Follow-up studies using human myeloma cell lines (HMCLs) as the principal experimental model system demonstrated that enforced expression of FOXM1 increased growth, survival and clonogenicity of myeloma cells, whereas knockdown of FOXM1 abolished these features. In agreement with that, constitutive upregulation of FOXM1 promoted HMCL xenografts in laboratory mice, whereas inducible knockdown of FOXM1 led to growth inhibition. Expression of cyclin-dependent kinase 6 (CDK6) and NIMA-related kinase 2 (NEK2) was coregulated with FOXM1 in both HMCLs and myeloma patient samples, suggesting interaction of these three genes in a genetic network that may lend itself to targeting with small-drug inhibitors for new approaches to myeloma therapy and prevention. These results establish FOXM1 as high-risk myeloma gene and provide support for the design and testing of FOXM1-targeted therapies specifically for the FOXM1 High subset of myeloma.
INTRODUCTION
The prognosis of patients with multiple myeloma (MM), a difficultto-cure blood cancer, depends in large measure on the genetic makeup of the myeloma cell. This is reflected in risk stratification models that consider cytogenetic features of myeloma, such as occurrence of oncogene-activating chromosomal translocations, and molecular features, such as gene expression changes 1 measured with the assistance of the UAMS-70, 2 EMC-92 (ref. 3) or REL-17 (ref. 4) gene test, to assign newly diagnosed cases to either standard-or high-risk groups. The distinction is clinically relevant because patients with high-risk myeloma have poor outcomes. Whereas overall survival (OS) for patients with standard-risk myeloma is 6-7 years, that for high-risk disease is no more than 2-3 years-despite the application of aggressive, risk-adapted therapies that include new myeloma drugs and, for eligible patients, high-dose therapy followed by autologous stem cell transplantation. 5 The unmet medical need of high-risk myeloma calls for dedicated efforts to elucidate the underlying genetic networks and develop approaches for their therapeutic targeting. This study demonstrates the involvement of the transcription factor forkhead box M1 (FOXM1) in a significant subset of high-risk myeloma (~15%) and suggests that FOXM1 provides a molecularly targeted treatment opportunity specifically for this group of patients.
In 2010, based on its enormous potential for the diagnosis and therapy of solid cancers, the AAAS journal Science bestowed upon FOXM1 the 'Breakthrough of the Year' award. FOXM1, a member of the large forkhead box (FOX) family of proteins (n≈50), is a validated oncogene in carcinomas, 6 but has received little attention in myeloma and related plasma cell malignancies. Findings implicating FOXM1 in the maintenance and self-renewal of carcinoma stem cells 7 have raised the question of whether it is similarly important for the putative myeloma stem cell 8 -yet the elusiveness of this cell 9 stands in the way of resolving the issue. Consistent with results that the expression of FOXM1 is tightly regulated in normal cells to ensure mitotic fidelity throughout the cell cycle, 10 deregulated expression of FOXM1 in carcinoma cells leads to centrosome amplification, mitotic catastrophe and other cytogenetic aberrations typically seen in cancer cells. 11 Whether FOXM1 governs genomic instability of MM, 12 a notorious but illexplained feature of the neoplasia, is unclear. In diffuse large B-cell lymphoma, in which levels of the FOXM1 mRNA and the encoded protein are high, targeted inhibition of FOXM1 augments cell killing when combined with normally subtoxic doses of the proteasome inhibitor, bortezomib. 13 Whether this holds true for MM has not been established.
Our interest in FOXM1 began with a comparative gene expression analysis of B-lymphoma counterparts in humans and mice, implicating the transcription factor in an evolutionarily conserved pathway of neoplastic B-cell development.
14 Further encouraged by new evidence indicating that FOXM1 (1) drives tumor development and progression [15] [16] [17] [18] [19] by virtue of a complex mechanism that includes enhanced cell proliferation, migration and invasion, 6 regulation of the DNA damage response 20 and changes in the cancer epigenome, 21 (2) promotes cancer cell resistance to ionizing radiation 22 and cytotoxic drugs, (3) governs, in part, the survival and tissue-regenerating capacity of both normal hematopoietic stem cells 24 and malignant stem cell-like cells, 25 (4) links acquired resistance to cancer therapy with cancer stemness 26 and (5) owing to the development of specific small-molecule inhibitors, 27 it may soon be targeted more effectively than possible in the past; 28 we here decided to evaluate whether FOXM1 might have an important but heretofore overlooked role in plasma cell myeloma.
MATERIALS AND METHODS
FOXM1 expression and survival analysis in patients with myeloma Levels of FOXM1 mRNA in myeloma cells were determined using Affymetrix U133Plus 2.0 microarrays (Affymetrix, Santa Clara, CA, USA) as described previously. 1 Results are available in the NIH Gene Expression Omnibus (GEO) under accession number GSE2658. Microarray data on monoclonal gammopathy of undetermined significance and normal plasma cells are available at GSE5900. Statistical analysis of microarray results relied on GCOS1.1 software (Affymetrix), including log-rank tests for univariate association with disease-related survival.
HMCLs, antibodies and reagents
Human myeloma cell line (HMCLs), designated H929 or APR1, were chosen for studies on inducible knockdown (KD) of FOXM1. HMCLs, CAG or XG1 were used for studies on constitutive overexpression (OE) of FOXM1. All four cell lines had secretion of IgA [29] [30] [31] [32] and in vitro culture conditions (37°C, 5% CO 2 ) in common. Oncogene-activating chromosomal translocations took the form of t(4;14) in case of H929 cells, 33 t(11;14) in XG1 cells 30 and t(14;16) in ARP1 and CAG cells. 33, 34 Gene expression spikes on microarrays corresponded to the translocation status: FGFR3 and WHSC1 (better known as MMSET) in case of H929 cells, CCND1 (cyclin D1) in XG1 cells and MAF (c-MAF) in ARP1 and CAG cells. 35 The status of the tumor suppressor p53 was wild type in case of H929 cells, 36 mutated in XG1 cells 37 and null in ARP1 and CAG cells. 34 Antibodies for western blotting were purchased from Santa Cruz Biotechnology (Dallas, TX, USA) (FOXM1, catalog number sc-500; CDK6 (cyclin-dependent kinase 6), sc-7961; β-actin, sc-47778) or Cell Signaling Technology (Danvers, MA, USA) (caspase-8, 4927; cleaved caspase-8, 9496; caspase-9, 9502; caspase-3, 9668; cleaved caspase-3, 9661; PARP, 9542). Dox and thiostrepton (TS) were from Sigma-Aldrich (St Louis, MO, USA).
Quantitative, reverse transcription polymerase chain reaction Total RNA was extracted using Quick-RNA MiniPrep (Zymo Research, Irvine, CA, USA) and reverse transcribed using oligo dT primers and SuperScript III RT (Invitrogen, Carlsbad, CA, USA). Data analysis relied on the ΔΔCt method. Primers were purchased from Integrated DNA Technologies (Coralville, IA, USA). Sequences are available upon request.
Western blotting and co-immunoprecipitation assays
Whole myeloma cell lysates were prepared using the Mammalian Cell Extraction Kit (K269-500) from Biovision (Milpitas, CA, USA). Proteins (30 μg per sample) were fractionated on 4-12% polyacrylamide gels blocked with 5% non-fat milk in Tris-buffered saline containing 0.05% Tween-20. Proteins were transferred to nitrocellulose membranes, incubated with primary antibody (dilution 10 − 3 ) overnight (4°C) and visualized with horse radish peroxidase-conjugated secondary antibody using SuperSignal West Pico (Pierce Biotechnology, Rockford, IL, USA). Blots were stripped, reprobed for β-actin and evaluated by densitometry to estimate protein abundance. Co-immunoprecipitations (co-IPs) using the Pierce Direct Magnetic IP/Co-IP Kit (Thermo Scientific, Rockford, IL, USA) and antibodies to FOXM1 and CDK6 were performed as recently described. 38 IgG from Bethyl Laboratories (Montgomery, TX, USA) was used as control.
Soft-agar clonogenicity assay
Clonogenic growth of myeloma was evaluated by seeding 1 × 10 4 cells in 0.5 ml RPMI 1640 (Invitrogen) supplemented with 0.33% agar and 10% FBS. Cells were grown in vitro (37°C, 5% CO 2 ) for 3 weeks, replenishing cell culture medium twice weekly. In some cases, cells were treated during weeks 2 and 3 with the FOXM1-inhibiting thiazole antibiotic, TS. Cell clones, defined as tight aggregates of ⩾ 40 myeloma cells, were enumerated using photographic images of soft-agar plates uploaded to Image J.
Cell proliferation and viability
Cell proliferation rate and viability were determined in 6-well plates using a hemacytometer and the trypan blue exclusion assay (0.4% dye in phosphate-buffered saline, pH 7.3).
Myeloma xenografts in immune-compromised laboratory mice Low and FOXM1 High , respectively. This is indicated by the horizontal, labeled arrow pointing left. (b) Reduced EFS and OS in newly diagnosed TT2 patients harboring high FOXM1 levels. Of 351 myeloma cases, 316 (90%) had low FOXM1 levels (blue curve) and 35 (10%) had high FOXM1 levels (red curve). EFS and OS data were available from 186 (53%) and 113 (32%) patients, respectively. (c) Mean values of FOXM1 levels in eight molecular subgroups of MM: CD1, CCND1/CCND3 group 1; CD2, CCND1/CCND3 group 2; HY, hyperdiploid; LB, low bone disease; MF, MAF/MAFB; MS, MMSET; MY, myeloid; PR, proliferation.
2 FOXM1 is significantly elevated in MF myelomas as compared with six subgroups with low FOXM1 levels (open squares), and in the PR myelomas as compared to four such subgroups (closed squares), as assessed using the Bonferoni t-test. The number of patients within each molecular subgroup who exhibit the standard-or high-risk UAMS-70 gene signature is indicated at the bottom. In total, 46 of 351 patients fell into the high-risk category, with at least one case in each of the molecular subgroups except CD2. (d) FOXM1 expression in high-risk MM, as defined by the UAMS-70 gene signature (n = 46), is elevated compared with that in low-risk MM (n = 305; Mann-Whitney test).
respectively, of NSG (NOD scid gamma) mice (Jackson Laboratory, Bar Harbor, ME, USA). To induce FOXM1 KD in incipient tumors, Dox (2 mg/ml) was added to the drinking water, beginning on day 10 following myeloma cell transfer.
Similarly, to assess the effect of FOXM1 OE on myeloma growth, paired samples of CAG cells (2 million in each flank) that expressed either elevated levels of FOXM1 (FOXM1 OE ) or normal levels (FOXM1 N ) were transferred subcutaneously to NSG mice (Jackson Laboratory). After 10 days, some mice were treated with intraperitoneal administrations of TS (30 mg/kg) twice weekly. In all cases, tumor growth was measured two to three times weekly, using a pair of calipers. Mice were killed using CO 2 asphyxiation when tumors reached 20 mm in diameter. All studies were approved under protocol 1301010 of the Institutional Animal Care and Use Committee of The University of Iowa.
Statistical analysis
Two-tailed Student's t-test was used to compare two experimental groups. One-way analysis of variance was used to evaluate more than two groups. The Kaplan-Meier method was used to determine myeloma patient survival in accordance with FOXM1 expression. In all cases, P ⩽ 0.05 was considered significant.
RESULTS
Heightened FOXM1 expression predicts poor survival in patients with myeloma To evaluate the possibility that FOXM1 is important for myeloma, we analyzed a well-annotated, mature data set, designated total therapy 2 (TT2), for which microarray-based gene expression and clinical outcome data were available. The levels of FOXM1 is a high-risk MM gene C Gu et al patients with newly diagnosed myeloma from that data set are presented in Figure 1a , according to increasing gene expression. With 200 units of FOXM1 message used as a cutoff, the great majority of cases (316/351, 90%) exhibited the same expression levels seen in normal plasma cells from the bone marrow (BM; n = 22) or in BM plasma cells from individuals with monoclonal gammopathy of undetermined significance (n = 44), a precursor of frank myeloma. 39 However, in 10% of myelomas (35/351) FOXM1 levels were grossly elevated. The distinction between high and low FOXM1 was of prognostic significance, as both event-free survival (EFS) and OS were reduced in cases exhibiting high FOXM1 expression (Figure 1b) . A very similar fraction of 'FOXM1
High ' myelomas (18/149, 12.1%; Supplementary  Figure 1a ) associated with the same kind of survival disadvantage (Supplementary Figure 1b) was seen in the Total Therapy 3 (TT3) cohort, which comprised intensively treated patients (n = 149) who had received tandem autologous stem cell transplantation and bortezomib/thalidomide-based induction and maintenance. 40 Similarly, elevated FOXM1 message predicted poor OS of patients with myeloma (n = 247) treated upfront using high-dose therapy/ autologous stem cell transplantation at the University of Heidelberg (Heidelberg, Germany) (Supplementary Figure 2) . 41 In agreement with the variable FOXM1 message levels seen in TT2/3 myelomas, a pilot immunolabeling study of archival myelomaladen BM sections pointed to variable amounts and distribution patterns of FOXM1 protein in myeloma cells (Supplementary Figure 3) . These findings indicated that upregulation of FOXM1 in a subset of myeloma (10-12%) leads to inferior outcome.
FOXM1 is a high-risk myeloma gene We asked whether heightened FOXM1 expression in the TT2 cohort might be associated with a particular molecular subgroup of myeloma. Figure 1c presents the mean values of FOXM1 levels in eight widely recognized subgroups, showing that elevated FOXM1 was particularly prevalent in two known to confer high risk in terms of clinical course and outcome: MAF/MAFB (MF) and proliferation (PR). A more recently developed molecular genetic approach to distinguishing high-and standard-risk disease, that is, the UAMS-70 gene signature, 2 afforded another way of testing whether upregulated FOXM1 might be a feature of high-risk myeloma. Statistical comparison of the mean FOXM1 levels in the 46 and 305 cases identified as high and standard risk according to this signature supported this contention (Figure 1d ). In sync with that, not only was FOXM1
High status statistically linked (χ 2 contingency analysis) with a positive score in the 70-gene test (P o 10 − 4 ) but almost two-thirds of the UAMS-70 high-risk cases (29/46, 63%) fell into the PR (n = 20) and MF (n = 9) subgroups of myeloma (indicated by red squares in Figure 1c, bottom) . The TT3 myelomas exhibited the same preponderance of FOXM1 High in the MF/PR subgroups and the same association of FOXM1
High status and positive 70-gene test score seen in the TT2 sample ( Supplementary Figures 1c and d) . The findings in more than 500 myelomas from the TT2/3 studies led us to conclude that FOXM1 is a bona fide high-risk myeloma gene.
Inducible downregulation of FOXM1 inhibits myeloma cells in vitro
Following up on the clinical observations described above, we decided to elucidate the role of FOXM1 in myeloma biology using two independent HMCLs, designated H929 and ARP1, that harbored ample amounts of FOXM1 protein. Genetic targeting of FOXM1 retards myeloma growth in mice To determine whether inducible KD of FOXM1 inhibits myeloma in vivo, we xenografted FOXM1 KD and FOXM1 N H929 cells under the skin of the left and right abdominal flank of NSG mice (n = 5), respectively. Ten days after in vivo transfer of two million cells to each side, the mice were administered Dox in the drinking water to induce the expression of FOXM1-targeted or scrambled shRNA in the malignant plasma cells (Figure 3a, top) . Tumor diameters were measured daily, using a pair of calipers, to compare the growth rate of the paired FOXM1 KD OE xenografts more effectively than FOXM1 N xenografts. (a) Scheme of experimental approach (top) and photographic images of myeloma xenografts harvested upon study termination on day 28 (bottom). FOXM1
OE and FOXM1 N CAG cells were generated using in vitro lentiviral gene transduction, followed by xenografting subcutaneously into the right and left flank of NSG hosts, respectively. One half of the study group was treated with TS (30 mg/kg intraperitoneally twice weekly) beginning on day 10 after cell transfer, whereas the other half was left untreated. shRNA during the 28-day growth period. These results demonstrated that genetic targeting of FOXM1 inhibits myeloma in vivo.
Enforced expression of FOXM1 promotes myeloma in vitro
To complement the KD studies described above with the opposite experimental approach, we assessed whether enforced transgenic expression of FOXM1 might enhance myeloma growth. To that end, we transfected two independent HMCLs containing moderate amounts of FOXM1 protein, CAG and XG1, with lentivirus that encoded a FOXM1 cDNA gene under control of the EF1α promoter. Compared with cells transduced with noncoding 'empty' virus that left FOXM1 levels unchanged (FOXM1 N , used as control), cells overexpressing FOXM1 (FOXM1 OE ) contained elevated amounts of FOXM1 message (Figure 4a, top) and FOXM1 protein (Figure 4a, bottom) . Upregulation of FOXM1 promoted cell growth (Figure 4b ), which was abolished by the FOXM1-inhibiting thiazole antibiotic, TS 42 ( Supplementary Figure 5a) . Increased growth of FOXM1 OE cells was attributed to enhanced cell cycle progression (not shown) and survival. The latter was reflected by less pronounced activation of PARP and caspases in FOXM1
OE cells compared to FOXM1 N cells (Figure 4c ). Clonogenic growth in soft agar was moderately heightened (by~30%) in untreated FOXM1
OE vs FOXM1 N cells, but more significantly elevated (2-3-fold) in TS-treated FOXM1 OE vs FOXM1 N cells (Supplementary Figures 5b and c) . These results agreed with the FOXM1 KD studies and strengthened the contention that FOXM1 regulates growth and survival of myeloma cells in vitro.
OE of FOXM1 promotes myeloma xenografts in NSG mice
We transferred FOXM1 OE and FOXM1 N CAG cells to NSG mice treated with TS or left untreated (Figure 5a, top) . In all cases, FOXM1
OE tumors harvested at study endpoint (day 28) were larger than the FOXM1 N tumors (Figure 5a, bottom) . In untreated mice, the mean weight of FOXM1 OE tumors (3.97 g) was significantly higher compared with that of FOXM1 N tumors (0.848 g): a ratio of 4.7 (Figure 5b) . The OE-to-N ratio (2.03 g/0.432 g, 4.7) was the same in TS-treated mice (Figure 5b ), which agreed with the expectation that TS inhibits FOXM1-expressing tumors, but did not support the possibility that FOXM1 OE tumors were more sensitive to the drug compared with that of their FOXM1 
to the contention that FOXM1 promotes myeloma in vivo, yet also indicated that TS may not be as active in mice as it is in vitro.
Coordinated expression of FOXM1 and CDK6 in myeloma To elucidate the mechanism by which FOXM1 promotes myeloma, we followed up on publicly available UCSC ChIP-Seq results and published findings, 43 both indicating that CDK6 is a transcriptional target of FOXM1 in normal and malignant cells. There is also strong evidence that FOXM1 is a direct phosphorylation target of CDK6 in cancer, suggesting a positive autoregulatory FOXM1-CDK6 feedforward loop that supports the malignant state. 44 Co-IP analysis of FOXM1 OE CAG and XG1 cells-which demonstrated that antibody to CDK6 (bait) pulled down FOXM1 (Figure 6a, top) , whereas antibody to FOXM1 (bait) pulled down CDK6 (Figure 6a , bottom)-pointed to physical interaction of both proteins in myeloma cells. Codetection of FOXM1 and CDK6 in FOXM1 OE CAG cells by means of immunofluorescence microscopy supported this interpretation (not shown). qRT-PCR (Figure 6b , top) and western blotting (Figure 6b , bottom) of FOXM1 KD and FOXM1 N H929 and ARP1 cells showed that FOXM1 and CDK6 expression may be coregulated in myeloma. Consistent with that, pharmacological inhibition of FOXM1 using TS caused a coordinated drop of FOXM1 and CDK6 message in CAG and XG1 cells-more steeply in FOXM1 OE than FOXM1 N cells (Figure 6c, top) . Corresponding changes in FOXM1 protein levels were also seen, but their magnitude was not as high as in case of mRNA (Figure 6c,  bottom) . In sync with the laboratory findings, FOXM1 and CDK6 expression were correlated in the TT2 and TT3 patient cohorts (Supplementary Figure 5b) and predictive of survival (Supplementary Figure 5c) . Interestingly, before adopting the UAMS-70 gene signature for stratifying standard-and high-risk myeloma, 2 a 3-gene minisignature had been developed for the same purpose. It relied on CDK6; one of its regulators, CKS1B, which encodes a member of the highly conserved cyclin kinase subunit 1 family of proteins; 45 and OPN3 (opsin 3), the role of which in myeloma is obscure (FZ, unpublished result).
Coexpression of FOXM1 and NEK2 in myeloma To identify additional network genes that may collaborate with FOXM1 in promoting myeloma, we interrogated the MMRC data set available online for genes tightly coexpressed with FOXM1 (Figure 7a ). Among the top 10 genes (r 2 = 0.838) was NIMA-related kinase 2 or NEK2. Because NEK2 is not only a well-established transcriptional target of FOXM1 in various cell lineages 46, 47 but also a driver of drug resistance in myeloma and other cancers, [48] [49] [50] we sought to confirm the coexpression of NEK2 and FOXM1 in independent data sets. This was the case in TT2 and TT3 (Supplementary Figure 6a Cases were stratified as high or low expressers when both FOXM1 and NEK2 message were above (indicated in red) or below (black) the medium level in the TT2 data set. All remaining cases (i.e., FOXM1 High /NEK2 Low or FOXM1 Low /NEK2 High ) were designated as medium expressers (blue). EFS and OS in all three groups was plotted and statistically compared using log-rank analysis.
FOXM1 is a high-risk MM gene C Gu et al analysis using this gene list as the input revealed a FOXM1-dependent network of transcription factors, DNA replication and cell division pathways in myeloma (Supplementary Figure 6d) . These in silico findings prompted us to determine whether FOXM1 and NEK2 might be coexpressed in the four HMCLs used throughout this study. Western blotting showed that FOXM1 and NEK2 proteins shifted coordinately in accordance with FOXM1 status in four of four cell lines (Figure 7b, top) . At the message level, results were less consistent; that is, although NEK2 mRNA dropped upon KD of FOXM1 in H929 and ARP1 cells (Figure 7b , bottom), NEK2 did not rise upon OE of FOXM1 in CAG and XG1 cells (results not shown). Despite the latter finding, FOXM1 and NEK2 expression status was statistically linked with survival in the TT2 cohort (Figure 7c) . These results provided evidence that FOXM1 and NEK2 are coregulated in myeloma.
DISCUSSION
The main finding of this study is clinical and experimental evidence for the involvement of FOXM1 in a relatively small (~15%) but aggressive subset of myeloma (chiefly subgroups MF and PR). FOXM1 expands the list of candidate genes uncovered by us 35, 38, 48, 51 and others, 52, 53 which seem to render myeloma a high-risk disease by regulating pathways of tumor progression and stemness, acquisition of drug resistance and, ultimately, refractory relapse. A distinctive feature of FOXM1, compared with all other candidate genes identified thus far, is its discovery in a comprehensive gene expression analysis of mature B-cell lymphoma counterparts in humans and mice.
14 Cross-species analyses of this sort, which afford a unique and powerful approach to identifying genetic networks of neoplastic growth conserved over millions of years of evolution, have been successfully used in research on solid cancers but largely neglected in myeloma. 14 The results on FOXM1 reported here demonstrate the utility of this approach for myeloma and suggest that comparative oncogenomics of myeloma-like tumors in genetically engineered mouse models may not only further our understanding of the natural history of myeloma but also reveal new targets for treatment and prevention. The ongoing development of new genetically engineered mouse models [54] [55] [56] and continuous refinement of established ones [57] [58] [59] are generating great promise along this line. The results reported here may be summarized in a working model of FOXM1's function in myeloma (Figure 8a ), which considers (1) the gene's coregulation with CDK6 and NEK2, (2) the output of a network analysis that relied on the GeneMANIA online tool to predict genetic interactions of FOXM1 in myeloma cells ( Figure 8b ) and (3) the ability of a novel 3-gene minisignature, comprised of FOXM1, CDK6 and NEK2, to prognosticate survival of patients with myeloma (Figure 8c ). Although the underlying molecular genetics of the interaction depicted in Figure 8a needs to be elucidated in greater depth, the scheme may provide a useful blueprint for designing combination treatments for FOXM1 High myelomas. This may take advantage of smallmolecule inhibitors of (a) FOXM1, such as FDI-6, which binds directly to the transcription factor and displaces it from genomic targets in cancer cells, 27 (b) CDK6, such as palbociclib, which is not 25 and that the FOXM1 target, CDK6, serves as a key regulator of leukemia stem cell activation, 64 raise the possibility that the interaction of FOXM1 and CDK6 in myeloma is also important for stemness. Additionally, FOXM1 may collaborate with NEK2 to drive resistance of myeloma cells to cancer therapy, given that NEK2 has been implicated in acquired drug resistance of many cancers [48] [49] [50] and specifically shown to activate certain ABC drug transporters in myeloma. 48 Specific inhibitors of all three genes have been developed. Palbocicblib has already demonstrated activity in clinical trials on myeloma. (b) Genetic interaction network of FOXM1, CDK6 and NEK2 (indicated in black to the left) generated with the help of the GeneMANIA online tool. Blue and pink lines denote pathways and physical interactions, respectively. Network genes are indicated by gray circles to the right that are labeled. The network's apparent enrichment for ubiquination genes (not shown) points to the proteasome, suggesting in turn that the FOXM1-CDK6-NEK2 network core is involved in the response of myeloma cells to proteasome inhibition, a widely used treatment for myeloma. (c) Kaplan-Meier plots of EFS (left) and OS (right) of patients with myeloma from the TT2 cohort stratified according to high levels (red) or low levels (black) of FOXM1, CDK6 and NEK2 message upon microarray analysis. Myelomas containing higher than median amounts of mRNA of all three genes were designated as high (n = 80), whereas myelomas that did not meet this criterion were designated as low (n = 271). The differences in survival were significant using log-rank analysis (P o0.05).
highly specific (it also targets CDK4) but has already demonstrated therapeutic activity (in conjunction with bortezomib and dexamethasone) in a phase 1/2 clinical trial of relapsed/refractory MM 60 and (c) NEK2, such as aminopyridine scaffold compounds, which inhibit NEK2's kinase activity, 61 or unrelated inhibitors, which trigger NEK2 degradation indirectly, using a mechanism that involves the disruption of NEK2 binding to kinetochore complex component, NDC80, better known as highly expressed in cancer 1 or HEC1. 62 Despite broad cancer-suppressing activities, 63 the cyclic oligopeptide antibiotic, TS, which has been used here as a FOXM1-inhibiting compound, is an unlikely candidate for further therapeutic development because its extensive use in veterinary medicine revealed severe toxicity issues.
In conclusion, FOXM1 appears to be a bone fide high-risk myeloma gene that interacts with CDK6 and NEK2 to facilitate myeloma xenografts in mice and promote the growth, clonogenic self-renewal and survival of myeloma cells in vitro. Clinical studies are warranted to further validate FOXM1 as a potential therapeutic target in FOXM1
High high-risk myeloma.
